SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

Strona główna・Stock List・Vetoquinol SA

Vetoquinol SA

Closed

SectorHealthcare

79.2 0.64

Buy Sell

Overview

Share price change

24h

Current

Min

78.5

Max

80.1

Key metrics
By Trading Economics
Income	25M
Sales	10M 268M
P/E Sector Avg	15.373 66.418
Profit margin	9.734
Employees	2,497
EBITDA	252M 301M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+37.16% upside

Market Stats
By TradingEconomics
Market Cap	-7.1M 928M
Previous open	78.56
Previous close	79.2

News Sentiment

By Acuity

50%

154 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

72.6 / 75.1 Support & Resistance

Vetoquinol SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 kwi 2026, 23:25 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 kwi 2026, 22:45 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 kwi 2026, 18:03 UTC

Earnings

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 kwi 2026, 23:58 UTC

Earnings

Review & Preview: Earnings Time -- Barrons.com

13 kwi 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 kwi 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 kwi 2026, 23:01 UTC

Earnings

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 kwi 2026, 23:01 UTC

Earnings

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 kwi 2026, 23:01 UTC

Earnings

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 kwi 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 kwi 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 kwi 2026, 21:26 UTC

Major News Events

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 kwi 2026, 21:23 UTC

Earnings

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 kwi 2026, 21:16 UTC

Earnings

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

13 kwi 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 kwi 2026, 20:34 UTC

Earnings

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 kwi 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 kwi 2026, 19:50 UTC

Market Talk

Major News Events

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 kwi 2026, 19:27 UTC

Market Talk

Major News Events

Correction to Precious Metals Market Talk on April 9

13 kwi 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 kwi 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 kwi 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 kwi 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer Comparison

Price change

Vetoquinol SA Forecast

Price Target

By TipRanks

37.16% upside

12 Months Forecast

Average 110 EUR 37.16%

High 110 EUR

Low 110 EUR

Based on 1 Wall Street analysts offering 12 month price targets forVetoquinol SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Vetoquinol SA - Dist in the past 3 months.

Technical Score

By Trading Central

72.6 / 75.1Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

154 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.